Carlyle to buy 20% of Piramal's India pharma business
The Carlyle Group has agreed to invest approximately $490 million for a 20% stake in pharmaceutical division of India’s Piramal Enterprises, which has interests ranging from outsourced drug development to an ophthalmology joint venture with Allergan.
The transaction values Piramal Pharma at $2.78 billion, with an upside component of up to $360 million depending on the company’s performance over the coming year, according to a statement. The size...
More on South Asia
Latest News
Fund focus: Firstred's advisory angle
Firstred Capital has already completed six deals from its debut fund, making commitments that are flexible in structure to Chinese companies that need its M&A expertise
4Q analysis: Growth spurt
Technology-enabled businesses in China and India are the beneficiaries of a resurgence in growth capital deal flow; Japan is the sole stand-out in fundraising; IPOs continue to shine as overall exits struggle
Chinese financial education start-up raises $100m
Erwan Technology, a China-based wealth management education platform, has secured nearly $100 million in funding across Series D and E rounds.
Investors question eligibility for HK carried interest tax concession
Fund-of-funds and family offices could be excluded from Hong Kong’s proposed carried interest tax concession, industry participants have warned.